Exagen Inc. Appoints Chas McKhann to Board of Directors

Exagen Inc. has appointed Chas McKhann to its Board of Directors, effective July 10, 2025. McKhann is a seasoned executive with over 25 years of experience in the life sciences industry, including leadership roles in several medical technology companies. He has a proven track record of leading turnaround and transformational growth, including serving as CEO of Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific. McKhann holds a B.A. in Political Science and an M.B.A. from Stanford University.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of experience in the life sciences industry, including leadership roles at multiple medical technology companies [1].

McKhann's extensive background includes serving as Board member, President, and CEO of Silk Road Medical and Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific. Prior to these roles, he was Chief Commercial Officer at Torax Medical and Intersect ENT. McKhann holds a B.A. in Political Science and an M.B.A. from Stanford University [1].

John Aballi, President and CEO of Exagen, expressed his excitement about McKhann's appointment: "I couldn’t be more excited to welcome Chas to the Board of Directors at Exagen. His exceptional leadership across multiple innovative life science companies and deep commercial expertise will be invaluable as we continue to drive growth and advance patient care" [1].

McKhann stated, "I’m honored to join the Board of Directors at Exagen, a company transforming autoimmune diagnostics through innovation and dedication to patient care. I look forward to working alongside the leadership team and fellow board members to help drive strategic growth and create long-term value for patients, providers, and shareholders" [1].

Exagen Inc. is committed to transforming care for patients with chronic and debilitating autoimmune conditions. The company's flagship product, AVISE® CTD, enables clinicians to diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen's laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results [1].

Forward-looking statements in the press release include Exagen's goals, strategies, and ambitions, as well as potential future financial and business performance. These statements are based on Exagen's current beliefs and expectations and are subject to risks and uncertainties inherent in the company's business [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9496466/exagen-inc-appoints-chas-mckhann-to-board-of-directors